In-depth guide

UPDATED JUN 2026

Talcum Powder Settlement Amounts

Part of the Talcum Powder investigation

The short answer

Talcum powder settlement amounts vary significantly based on cancer type, severity, duration of talc use, and strength of evidence. Jury verdicts have ranged from $250,000 to $1.56 billion for individual plaintiffs.

Settlement tiers project ranges from $50,000 for moderate ovarian cancer claims to $5 million or more for severe mesothelioma or wrongful death cases. The Imerys Talc Trust ($850 million) provides an additional compensation pathway.

People's Justice Research TeamUpdated June 11, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

Free · Confidential · About 2 minutes · A case specialist responds within 1 business day

Your answers are never sold or shared without your consent.

Verdict History and Settlement Projections

The talcum powder litigation has produced some of the largest product liability verdicts in American history. The $1.56 billion Craft verdict (December 2025), the $2.12 billion Ingham verdict (reduced on appeal from $4.69 billion, 2018), and the $117 million Lanzo verdict (2018) demonstrate that juries are willing to award extraordinary amounts when confronted with evidence of J&J’s decades-long concealment. The $700 million consumer class action settlement (2023) and the $850 million Imerys Talc Trust (2025) provide additional compensation frameworks.

Individual case values in the talcum powder litigation depend on several factors. Cancer type is the most significant variable — mesothelioma cases are generally valued higher than ovarian cancer cases because mesothelioma is almost always fatal and the asbestos causation link is stronger. Within ovarian cancer claims, the stage at diagnosis, the duration of talc use, the strength of medical records, and the availability of pathological evidence (talc particles in tumor tissue) all affect valuation.

Three compensation tiers have emerged. Tier I (moderate) encompasses cases with documented talc use and a cancer diagnosis but limited additional evidence, with projected settlements of $50,000 to $200,000. Tier II (significant) covers cases with long-term documented use and comprehensive medical records, with projected settlements of $200,000 to $1 million. Tier III (severe) addresses mesothelioma, advanced/fatal ovarian cancer, and wrongful death cases, with projected settlements of $1 million to $5 million or more.

The Imerys Talc Trust and Multiple Compensation Pathways

The Imerys Talc Trust, established when Imerys Talc America emerged from bankruptcy in August 2025, provides an additional avenue for compensation. The $850 million trust — funded by $505 million from J&J and the remainder from Imerys — is available to both current and future talc claimants. Trust claims may be filed in addition to direct claims against J&J through the MDL or state court proceedings.

The existence of multiple compensation pathways is important for plaintiffs. Claims against J&J through the MDL and state courts, claims through the Imerys Trust, and potential additional settlements as bellwether trial results accumulate all represent distinct avenues for recovery. An experienced talcum powder attorney can evaluate which combination of claims is most advantageous for your specific situation.

The contingency fee structure means families owe no fee upfront. Attorney fees are typically 33–40% of the total recovery, and all case costs are advanced by the law firm. The initial consultation is free and confidential. Filing early ensures your claim is preserved and positioned for the best possible outcome as the litigation moves toward resolution.

Research & evidence

Scientific Evidence

meta-analysis

IARC Monograph Volume 136: Talc and Acrylonitrile

International Agency for Research on Cancer Working Group. (2024). IARC Monographs on the Identification of Carcinogenic Hazards to Humans

Key findings

  • Limited but consistent evidence in humans from epidemiological studies showing increased ovarian cancer risk with perineal talc use across multiple study designs and populations
  • Sufficient evidence of carcinogenicity in experimental animals, with talc causing tumors in multiple species and organ sites
  • Strong mechanistic evidence including chronic inflammation, oxidative stress, altered cell proliferation, and epigenetic alterations in exposed tissues
  • The upgrade to Group 2A reflects the accumulation of evidence since the 2006 Group 2B classification, including new large-scale epidemiological studies and improved mechanistic understanding
meta-analysis

Prospective Cohort Studies of Talc Use and Ovarian Cancer Risk

Harvard Nurses’ Health Study / Women’s Health Initiative Investigators. (2020). Journal of the National Cancer Institute / Journal of Clinical Oncology

Key findings

  • Consistent positive association between perineal talc use and ovarian cancer risk, with hazard ratios typically ranging from 1.20 to 1.40
  • Risk increased with duration of use, supporting a cumulative exposure model consistent with the chronic inflammation mechanism
  • The association was strongest for serous ovarian cancer, the most common and lethal histological subtype
  • Prospective study design provides stronger causal inference than case-control studies because talc use was reported before cancer diagnosis, eliminating recall bias
cross-sectional

Perineal Talc Use and Ovarian Cancer Risk: A Case-Control Study

Cramer DW, Welch WR, Scully RE, Wojciechowski CA. (1982). The Lancet

Key findings

  • Women who used talcum powder for perineal hygiene had an odds ratio of 1.92 for ovarian cancer compared to non-users
  • The risk increased with frequency and duration of use, suggesting a dose-response relationship
  • The study proposed the talc migration pathway: particles travel from the perineal area through the reproductive tract to the ovarian surface
  • Results were consistent across multiple cancer histological subtypes, supporting a general carcinogenic mechanism rather than subtype-specific effect

FAQ

Frequently Asked Questions

36 QUESTIONS

Yes. More than 63,000 lawsuits have been filed against Johnson & Johnson alleging that Baby Powder and other talc-based products caused ovarian cancer and mesothelioma. You may have a legal claim if you used J&J talcum powder products and were subsequently diagnosed with ovarian cancer, mesothelioma, fallopian tube cancer, peritoneal cancer, or endometrial cancer. The strongest claims involve long-term perineal use with a documented cancer diagnosis. Attorneys handle these cases on contingency. Fee arrangements vary, so confirm terms with any attorney you consult. The MDL 2738 in the District of New Jersey is actively coordinating thousands of federal cases, and state court proceedings continue nationwide.

Dive deeper

Related Guides

7 GUIDES

The full investigation

Part of the Talcum Powder Investigation